John Z. Ayanian, MD; Charles S. Fuchs, MD; Richard M. Stone, MD
This content is PDF only. Please click on the PDF icon to access.
To the Editor: Lovastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, the rate-limiting enzyme in cholesterol biosynthesis, lowers serum cholesterol in both familial (1) and nonfamilial (2) forms of hypercholesterolemia. Rhabdomyolysis, occasionally resulting in renal failure, has been reported in 13 patients receiving lovastatin therapy 9 of whom were also receiving cyclosporine or gemfibrozil therapy (3, 4). We report a case of severe rhabdomyolysis in a patient being treated with both lovastatin and erythromycin; the case potentially represents a new adverse drug interaction.
A 65-year-old man with a history of severe coronary artery disease and chronic renal failure had been
Ayanian JZ, Fuchs CS, Stone RM. Lovastatin and Rhabdomyolysis. Ann Intern Med. ;109:682–683. doi: 10.7326/0003-4819-109-8-682
Download citation file:
Published: Ann Intern Med. 1988;109(8):682-683.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use